Fabry Disease - Pipeline Analysis 2019
June 2019
76
About the Report
About the Report
Fabry Disease (also known as Anderson Fabry Disease) is a progressive X linked inherited genetic disorder of glycosphingolipid metabolism due to deficient or absent lysosomal a-galactosidase A activity. It is a devastating inborn error of metabolism with, particularly in the early stages, being played by cellular dysfunction and microvascular pathology being induced by lysosomal glycosphingolipid deposition.
Recombinant alpha-galactosidase A (alpha-Gal A), the enzyme that is deficient in patients with Fabry disease, and migalastat hydrochloride, an oral pharmacological chaperone that facilitates trafficking of alpha-Gal A to lysosomes, are therapeutic options for eligible individuals. The therapeutic management primarily focuses on the control of blood pressure, lipids, and proteinuria. ACE inhibitors and/or blockers are used in patients with proteinuria. Hypertension and hypercholesterolemia are be managed appropriately. The prophylaxis with anticoagulants is important in patients who have had ischemic attacks or stroke, and permanent cardiac pacing are considered in high-risk patients.
Emerging treatment strategies for Fabry disease involve the development of small molecule compounds, which are widely used for the treatment of a variety of diseases. Such small molecules account for approximately 80-90% of marketed drugs. Although enzyme replacement therapy is effective, there is a need for other therapeutic strategies, which can either serve as primary or supplemental treatments. Small molecule drug discovery is promising, as it could lead to new treatments for Fabry disease. The discovery of non-inhibitory chaperones, activators, or inhibitors of the enzymes that degrade glycosphingolipids, would be a breakthrough.
Currently the therapeutic pipeline of NPC Disease consists of approximately 9+ products in different stages of development and major drugs are in pre-clinical stage. The key players involved in the development of products for the treatment of Fabry Disease include Amicus Therapeutics (Fabry Gene Therapy); Freeline (FTL190); Greenovation Biotech (Moss-aGal); Idorsia Pharmaceuticals (Lucerastat); Moderna (mRNA-3630); Pharming (PGN005); Protalix Biotherapeutics (Pegunigalsidase alfa); Resverlogix Corp (Apabetalone); Sangamo Therapeutics (ST-920) and Sanofi Genzyme (Venglustat). Most products under development are small molecule and gene therapy.
The development and launch of these therapies are expected to lead to the better treatment and longer life span of the individuals with Fabry Disease.
Products
Companies
Amicus Therapeutics
Evotec
Freeline
Greenovation Biotech
Idorsia Pharmaceuticals
Moderna
Pharming
Protalix Biotherapeutics
Resverlogix Corp
Sangamo Therapeutics
Sanofi Genzyme
Table of Contents
Table of Contents
1. REPORT INTRODUCTION
1.1 Objective of the Study 8
1.2 Secondary Research 8
1.3 Scope of the report: 8
2. DISEASE OVERVIEW 9
2.1 Introduction 9
2.2 Etiology 10
2.3 Classification 11
2.4 Signs and Symptoms 12
2.5 Pathogenesis 14
2.5.1 Metabolic Defect 14
2.5.2 The Molecular Basis 15
2.5.3 Genotype/Phenotype Correlation 18
2.6 Diagnosis 19
2.6.1 Biochemical Diagnosis: 19
2.6.1.1 Measurement of a-Gal Activity in Cultivated Fibroblasts, Plasma, or Leukocytes 19
2.6.1.2 Measurement of a-Gal A Activity in Blood Spot Filter Paper 20
2.6.1.3 GL-3 Levels 20
2.6.2 Molecular Diagnosis 21
2.6.3 Molecular Analysis 21
2.7 Treatment 23
2.7.1 Clinical management of pediatric patients 24
2.7.1 Management of Fabry related pain in paediatric patients 24
2.7.1.1 Trigger management 24
2.7.1.2 Symptomatic therapy 25
2.7.1.2.1 Management of neuropathic pain 25
2.7.1.2.2 Management of psychological disturbances 26
2.7.2 Treatment Algorithm for the management of neuropathic pain in paediatric Fabry Disease patients 27
2.7.2.1 Enzyme replacement therapy 28
2.7.2.2 Recommendations for ERT initiation 29
2.7.3 Management in adults 30
2.7.3.1 Available Enzyme Replacement therapies 31
2.7.3.2 Initiation of enzyme replacement therapy 31
2.7.3.3 Expert panel recommendations for initiation of enzyme replacement therapy in adult patients with Fabry Disease 31
2.7.3.4 Adjunctive therapies 33
2.7.3.5 Non-ERT approaches for patients with specific mutations 34
2.7.4 Monitoring of adult patients with Fabry Disease 35
3. PIPELINE THERAPEUTICS AT A GLANCE 38
3.1 Pipeline Therapeutics at a Glance 38
4. COMPARATIVE ANALYSIS 39
4.1 Number of Products under Fabry Diseases 39
5. LATE PHASE PRODUCTS (PHASE III) 40
5.1 Comparative Analysis 40
5.2 Lucerastat: Idorsia Pharmaceuticals 40
5.2.1 Product Description 40
5.2.2 Research and Development 41
5.2.2.1 Clinical Studies 41
5.2.2.1.1 Phase III 41
5.2.2.1.2 Phase I 41
5.2.2.1.3 Results of Analysis 41
5.2.2.1.4 Results of Analysis II 42
5.2.3 Product Development Activities 42
5.2.3.1 Designation 42
5.2.3.2 Spin Off 43
5.3 Pegunigalsidase alfa: Protalix Biotherapeutics 44
5.3.1 Product Description 44
5.3.2 Research and Development 44
5.3.2.1 Clinical Studies 44
5.3.2.1.1 Phase III 44
5.3.2.1.2 Results of Analysis 45
5.3.2.1.3 Results of Analysis II 46
5.3.3 Product Development Activities 47
5.3.3.1 Designation 47
5.3.3.2 Agreement 47
5.3.3.3 Patent 48
5.3.3.4 Technology 48
6. MID PHASE PRODUCTS (PHASE II) 50
6.1 Comparative Analysis 50
6.2 Venglustat: Sanofi Genzyme 50
6.2.1 Product Description 50
6.2.2 Research and Development 51
6.2.2.1 Clinical Studies 51
6.2.2.1.1 Phase II 51
6.2.3 Product Development Activities 51
6.2.3.1 Designation 51
7. EARLY STAGE PRODUCTS (PHASE I) 53
7.1 Comparative Analysis 53
7.2 Apabetalone: Resverlogix Corp 53
7.2.1 Product Description 53
7.2.2 Research and Development 54
7.2.2.1 Clinical Studies 54
7.2.2.1.1 Phase II 54
7.3 Moss-aGal: Greenovation Biotech 55
7.3.1 Product Description 55
7.3.2 Research and Development 55
7.3.2.1 Clinical Studies 55
7.3.2.1.1 Phase I 55
7.3.2.1.2 Results of Analysis 56
7.3.3 Product Development Activities 56
7.3.3.1 Technology 56
8. PRE-CLINICAL STAGE PRODUCTS 58
8.1 Comparative Analysis 58
8.2 Fabry Gene Therapy: Amicus Therapeutics 58
8.2.1 Product Description 58
8.2.2 Product Development Activities 59
8.2.2.1 Agreement 59
8.3 FTL190: Freeline 60
8.3.1 Product Description 60
8.3.2 Research and Development 60
8.3.2.1 Pre-clinical Studies 60
8.3.3 Product Development Activities 61
8.3.3.1 Financing 61
8.4 mRNA-3630: Moderna 62
8.4.1 Product Description 62
8.5 PGN005 (a-galactosidase): Pharming 63
8.5.1 Product Description 63
8.6 ST-920: Sangamo Therapeutics 63
8.6.1 Product Description 63
8.6.2 Research and Development 64
8.6.2.1 Pre-clinical Studies 64
8.6.3 Product Development Activities 64
8.6.3.1 IND Acceptance 64
9. THERAPEUTIC ASSESSMENT 65
9.1 Assessment by Stage and Product Type 65
9.2 Assessment by Route of Administration 66
9.3 Assessment by Stage and Route of Administration 67
9.4 Assessment by Molecule Type 68
9.5 Assessment by Stage and Molecule Type 69
10. APPROVAL TIMELINES 70
10.1 Clinical Products Approval Timelines 70
11. ANALYST INSIGHTS 71
12. INACTIVE PRODUCTS 72
12.1 Comparative Analysis 72
12.2 Small Molecule Inhibitor: Evotec 72
12.2.1 Product Description 72
12.2.2 Product Development Activities 72
12.2.2.1 Collaboration 72
List of Figure
Figure 1: Typical Signs and Symptoms of Fabry Disease according to age 12
Figure 2: Some key mutations associated with the classic or later-onset Fabry Disease phenotype, GLA variants of unclear significance (VUS), and benign variants 15
Figure 3: a-galactosidase A gene mutations 16
Figure 4: Fabry disease X-linked Inheritance Pattern 17
Figure 5: Treatment Algorithm for the management of neuropathic pain in paediatric Fabry Disease patients 27
Figure 6: Total Number of Products in Fabry Disease 39
Figure 7: Late Stage Products (Phase III) 40
Figure 8: Mid Stage Products (Phase II) 50
Figure 9: Early Stage Products (Phase I) 53
Figure 10: Pre-clinical Stage Products 58
Figure 11: Assessment by Stage and Product Type 65
Figure 12: Assessment by Route of Administration 66
Figure 13: Assessment by Stage and Route of Administration 67
Figure 14: Assessment by Molecule Type 68
Figure 15: Assessment by Stage and Molecule Type 69
Figure 16: Approval Timelines for Clinical Products 70
Figure 17: Inactive Products 72
List of Table
Table 1: Criteria for Phenotype Classification 11
Table 2: Clinical evaluation and monitoring of pediatric patients with Fabry Disease 21
Table 3: Clinical evaluation and monitoring of adult patients with Fabry Disease 22
Table 4: Recommendations for initiation of ERT in pediatric patients with FD 30
Table 5: Recommendations for initiation of ERT in adult male and female patients with classic or later-onset mutations, or GLA VUS. 31
Table 6: Adjunctive support for the management of adult patients with Fabry Disease 34
Table 7: Recommended assessments and schedule for monitoring organ involvement in adult patients with Fabry Disease 36
Table 8: Total Number of Products in Fabry Disease 39
Table 9: Late Stage Products (Phase III) 40
Table 10: Clinical Trial Description: Lucerastat 42
Table 11: General Description: Lucerastat 43
Table 12: Clinical Trial Description: Pegunigalsidase alfa 47
Table 13: General Description: Pegunigalsidase alfa 49
Table 14: Mid Stage Products (Phase II) 50
Table 15: Clinical Trial Description: Venglustat 51
Table 16: General Description: Venglustat 51
Table 17: Early Stage Products (Phase I) 53
Table 18: Clinical Trial Description: Apabetalone 54
Table 19: General Description: Apabetalone 54
Table 20: Clinical Trial Description: Moss-aGal 56
Table 21: General Description: Moss-aGal 57
Table 22: Pre-clinical Stage Products 58
Table 23: General Description: Fabry Gene Therapy 59
Table 24: General Description: FTL190 61
Table 25: General Description: mRNA-3630 62
Table 26: General Description: PGN005 63
Table 27: General Description: ST-920 64
Table 28: Assessment by Stage and Product Type 65
Table 29: Assessment by Route of Administration 66
Table 30: Assessment by Stage and Route of Administration 67
Table 31: Assessment by Molecule Type 68
Table 32: Assessment by Stage and Molecule Type 69
Table 33: Approval Timelines for Clinical Products 70
Table 34: Inactive Products 72
Table 35: General Description: Small Molecule Inhibitor 73
1.
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.